Gold Falls Amid Trump's Reversal on European Tariffs
ByAinvest
Friday, Jan 23, 2026 2:38 pm ET1min read
BHC--
Bausch Health Companies Inc. reported a 10% drop in stock price following the failure of its Phase 3 program evaluating rifaximin to delay the first episode of hepatic encephalopathy in patients with cirrhosis. The failure of the program means that there is no successor to the blockbuster drug Xifaxan, which is a key revenue driver for the company.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet